PD-1 NSCLC Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Genor Biopharma, Shandong Boan Biotech, Pfizer, AstraZeneca, Lepu Biopharma, GSK

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, PD-1 Non-Small Cell Lung Cancer pipeline constitutes 30+ key companies continuously working towards developing 30+ PD-1 Non-Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The PD-1 Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"PD-1 Non-Small Cell Lung Cancer Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PD-1 Non-Small Cell Lung Cancer Market.

Some of the key takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report:

*
Companies across the globe are diligently working toward developing novel PD-1 Non-Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years.

*
PD-1 Non-Small Cell Lung Cancer companies working in the treatment market are Merck, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/ Hoffmann-La Roche, Regeneron/Sanofi, BeiGene, Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, Arcus Biosciences, Summit Therapeutics, Seagen,, and others, are developing therapies for the PD-1 Non-Small Cell Lung Cancer treatment

*
Emerging PD-1 Non-Small Cell Lung Cancer therapies in the different phases of clinical trials are- KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), TECENTRIQ (atezolizumab), LIBTAYO (cemiplimab-rwlc), TIZVENI (tislelizumab), GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, Zimberelimab, Ivonescimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, and others are expected to have a significant impact on the PD-1 Non-Small Cell Lung Cancer market in the coming years.

*
In May 2025, OmRx Oncology (OmRx), a clinical-stage biopharmaceutical company, has initiated a randomized Phase II trial for its oral PD-L1 inhibitor, OX-4224, targeting patients with non-small cell lung cancer (NSCLC). The company believes this small molecule could provide a more affordable and accessible alternative to existing antibody therapies. The open-label study plans to enroll about 50 metastatic NSCLC patients in India who have not previously received immune checkpoint inhibitors. OX-4224 will be assessed as a second-line monotherapy in this trial.

*
In January 2025, ImmunityBio, Inc. (NASDAQ: IBRX) has announced a new collaboration and supply agreement with BeiGene, Ltd. (soon to be renamed BeOne Medicines, Ltd.), a global oncology company. The partnership will support a Phase 3 confirmatory clinical trial (ResQ201A-NSCLC), which will evaluate the combination of BeiGene's PD-1 checkpoint inhibitor, tislelizumab, with ImmunityBio's ANKTIVA (nogapendekin alfa inbakicept-pmln). This randomized trial (NCT06745908) is designed to validate the efficacy and safety results seen in the earlier QUILT 3.055 study, aiming to demonstrate the potential of this dual immunotherapy approach in improving overall survival for patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have developed resistance to immune checkpoint inhibitors.

*
In April 2024, BeiGene announced that the European Commission (EC) has granted approval for TIZVENI (tislelizumab) as a treatment for NSCLC, covering three indications, including both first- and second-line use.

*
In January 2024, Gilead Sciences reported that the Phase 3 EVOKE-01 study did not achieve its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). The EVOKE-01 trial is assessing Trodelvy (sacituzumab govitecan-hziy; SG) against docetaxel in patients with metastatic or advanced NSCLC who have progressed following platinum-based chemotherapy and checkpoint inhibitor therapy.

*
In February 2024, The FDA has granted breakthrough therapy designation to BAY 2927088, an innovative oral small molecule tyrosine kinase inhibitor (TKI), for treating patients with unresectable or metastatic HER2-mutated non-small cell lung cancer (NSCLC).

PD-1 Non-Small Cell Lung Cancer Overview

PD-1, or programmed cell death protein 1, is a checkpoint protein on immune cells called T cells. It plays a crucial role in regulating the immune response by inhibiting T cells from attacking other cells in the body, including cancer cells. In some cancers, including non-small cell lung cancer (NSCLC), cancer cells can hijack the PD-1 pathway to evade the immune system's attack.

Get a Free Sample PDF Report to know more about PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight [https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr%5C]

Emerging PD-1 Non-Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:

*
KEYTRUDA (pembrolizumab): Merck

*
OPDIVO (nivolumab): Bristol-Myers Squibb/Ono Pharmaceutical

*
TECENTRIQ (atezolizumab): Genentech/ Hoffmann-La Roche

*
LIBTAYO (cemiplimab-rwlc): Regeneron/Sanofi

*
TIZVENI (tislelizumab): BeiGene

*
GB226: Genor Biopharma

*
BA-1104: Shandong Boan Biotechnology

*
PF-06801591: Pfizer

*
AZD2936: AstraZeneca

*
HX008: Lepu Biopharma

*
Dostarlimab: GlaxoSmithKline

*
INCMGA00012: Incyte Corporation

*
AK-112: Akeso Biopharma

*
Zimberelimab: Arcus Biosciences

*
Ivonescimab: Summit Therapeutics

*
Sasanlimab: Pfizer

*
Rilvegostomig: AstraZeneca

*
SGN-PDL1V: Seagen

PD-1 Non-Small Cell Lung Cancer Route of Administration

PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

PD-1 Non-Small Cell Lung Cancer Molecule Type

PD-1 Non-Small Cell Lung Cancer Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

*
PD-1 Non-Small Cell Lung Cancer Assessment by Product Type

*
PD-1 Non-Small Cell Lung Cancer By Stage and Product Type

*
PD-1 Non-Small Cell Lung Cancer Assessment by Route of Administration

*
PD-1 Non-Small Cell Lung Cancer By Stage and Route of Administration

*
PD-1 Non-Small Cell Lung Cancer Assessment by Molecule Type

*
PD-1 Non-Small Cell Lung Cancer by Stage and Molecule Type

DelveInsight's PD-1 Non-Small Cell Lung Cancer Report covers around 30+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further PD-1 Non-Small Cell Lung Cancer product details are provided in the report. Download the PD-1 Non-Small Cell Lung Cancer pipeline report to learn more about the emerging PD-1 Non-Small Cell Lung Cancer therapies [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the PD-1 Non-Small Cell Lung Cancer Therapeutics Market include:

Key companies developing therapies for PD-1 Non-Small Cell Lung Cancer are - Arcus Biosciences, GlaxoSmithKline, Pfizer, AstraZeneca, Seagen, MacroGenics, Roche, Summit Therapeutics, Qilu Pharmaceutical, Shandong New Age Pharmaceutical, Symphogen, and others

PD-1 Non-Small Cell Lung Cancer Pipeline Analysis:

The PD-1 Non-Small Cell Lung Cancer pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of PD-1 Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 Non-Small Cell Lung Cancer Treatment.

*
PD-1 Non-Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
PD-1 Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1 Non-Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about PD-1 Non-Small Cell Lung Cancer drugs and therapies [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

PD-1 Non-Small Cell Lung Cancer Pipeline Market Drivers

*
Increase in Patient Burden, development of Efficient Novel Treatments, increasing healthcare expenditures are some of the important factors that are fueling the PD-1 Non-Small Cell Lung Cancer Market.

PD-1 Non-Small Cell Lung Cancer Pipeline Market Barriers

*
However, uncertainty about the clinical response to PD-1/PD-L1 blockade therapy in NSCLC, NSCLC with driver mutations represent a challenging population and other factors are creating obstacles in the PD-1 Non-Small Cell Lung Cancer Market growth.

Scope of PD-1 Non-Small Cell Lung Cancer Pipeline Drug Insight

*
Coverage: Global

*
Key PD-1 Non-Small Cell Lung Cancer Companies: Merck, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/ Hoffmann-La Roche, Regeneron/Sanofi, BeiGene, Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, Arcus Biosciences, Summit Therapeutics, Seagen,, and others

*
Key PD-1 Non-Small Cell Lung Cancer Therapies: KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), TECENTRIQ (atezolizumab), LIBTAYO (cemiplimab-rwlc), TIZVENI (tislelizumab), GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, Zimberelimab, Ivonescimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, and others

*
PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment: PD-1 Non-Small Cell Lung Cancer current marketed and PD-1 Non-Small Cell Lung Cancer emerging therapies

*
PD-1 Non-Small Cell Lung Cancer Market Dynamics: PD-1 Non-Small Cell Lung Cancer market drivers and PD-1 Non-Small Cell Lung Cancer market barriers

Request for Sample PDF Report for PD-1 Non-Small Cell Lung Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. PD-1 Non-Small Cell Lung Cancer Report Introduction

2. PD-1 Non-Small Cell Lung Cancer Executive Summary

3. PD-1 Non-Small Cell Lung Cancer Overview

4. PD-1 Non-Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment

5. PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics

6. PD-1 Non-Small Cell Lung Cancer Late Stage Products (Phase II/III)

7. PD-1 Non-Small Cell Lung Cancer Mid Stage Products (Phase II)

8. PD-1 Non-Small Cell Lung Cancer Early Stage Products (Phase I)

9. PD-1 Non-Small Cell Lung Cancer Preclinical Stage Products

10. PD-1 Non-Small Cell Lung Cancer Therapeutics Assessment

11. PD-1 Non-Small Cell Lung Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. PD-1 Non-Small Cell Lung Cancer Key Companies

14. PD-1 Non-Small Cell Lung Cancer Key Products

15. PD-1 Non-Small Cell Lung Cancer Unmet Needs

16 . PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers

17. PD-1 Non-Small Cell Lung Cancer Future Perspectives and Conclusion

18. PD-1 Non-Small Cell Lung Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pd1-nsclc-pipeline-2025-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-genor-biopharma-shandong-boan-biotech-pfizer-astrazeneca-lepu-biopharma-gsk]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.